ArticleAnesthesiology2026
Intranasal Naloxone Reversal of Opioid-induced Respiratory Depression in Opioid-naive Individuals and Self-reported Daily Opioid Users.
Article in Anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting the Carotid Body Function With Big-KPharmacology research & perspectives · 2026Article
- Reversal, Risk, and Responsibility in the Era of Potent Opioids and Overdose.Anesthesiology · 2026Article
- Naloxone reversal of fentanyl-induced respiratory depression versus naloxone-induced precipitated withdrawal: anFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince current opioid overdose deaths occur mainly from potent synthetic opioids with high affinity for the opioid receptor, such as fentanyl and carfentanil, it is important to determine the efficacy of naloxone, particularly the intranasal formulation, in reversing opioid-induced respiratory depression. This study evaluated effectiveness of 4 mg intranasal naloxone (Narcan; Adapt Pharma Inc., USA) in reversing moderate respiratory depression induced by fentanyl and sufentanil in opioid-naive individuals and self-reported daily opioid users. Sufentanil was compared to fentanyl because of its higher affinity for the opioid receptor.
methodsIn this prospective, crossover trial, 12 opioid-naive individuals and 18 daily opioid users (morphine milligram equivalent, 291; range, 60 to 2,250 mg/day) received continuous fentanyl or sufentanil infusions, titrated to achieve 30 to 40% reduction in minute ventilation ( ). Participants were administered Narcan during steady-state respiratory depression. Primary endpoints included time to reversal of diminished and elevated end-tidal carbon dioxide concentration (pCO 2 ).
resultsNarcan restored within 2 to 4 min across all participants but showed delayed reversal of end-tidal pCO 2 (11 to 17 min), with pCO 2 recovery during sufentanil exposure in just 8 opioid-naive individuals and 10 daily opioid users. Hysteresis analysis showed for reversal onset/offset times (blood-effect-site equilibration half-lifes) of 0 to 1 min and for end-tidal pCO 2 2 to 11 min. Because of withdrawal symptoms, 7 of 18 daily opioid users participated once in the study. Study limitations included continuous opioid infusions that do not occur in real-world overdose settings.
conclusionsA single Narcan dose reversed moderate fentanyl- and sufentanil-induced respiratory depression, although effectiveness varied by endpoint and opioid receptor affinity. Rapid recovery suggests clinical utility of intranasal naloxone, but delayed and sometimes incomplete recovery of end-tidal pCO 2 , particularly during exposure to the high-affinity opioid sufentanil, indicates reversal inefficacy and persistence of respiratory instability. Further studies are needed to address optimal naloxone doses and alternative formulations to address high-dose potent opioid threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.